Showing results (2551-2560 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|July 10, 2025
Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancerRithika Rajendran, Coen J Lap, Siddharth Madapoosi, et al.
The Oncologist|July 9, 2025
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumorsMartin E Gutierrez, Shou-Ching Tang, John D Powderly, et al.
The Oncologist|July 7, 2025
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancerLorenzo Antonuzzo, Hidenori Takahashi, Joon Oh Park, et al.
The Oncologist|July 7, 2025
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)Wenwen Chen, Julia Majovski, Shailender Bhatia, et al.
The Oncologist|July 28, 2025
Global Variations in Oncology Professionals' Confidence Levels for Managing Antibody-Drug Conjugate Toxicities: A Cross-Continental SurveyMarina Campione, Michele Maffezzoli, Aruni Ghose, et al.
The Oncologist|July 24, 2025
Under the radar-frequency, timing, duration and trajectory of lower grade adverse events in clinical trials of anti-cancer therapiesKatherine E Francis, Sarah J Lord, Sandy Simon, et al.
The Oncologist|July 23, 2025
Exploring the Impact of first-line Durvalumab plus chemotherapy on advanced biliary tract cancer: A Systematic Review and Meta-AnalysisPatrick Reimann, Eva-Maria Schneider, Angela Djanani, et al.
The Oncologist|July 23, 2025
Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and ManagementAaron Lisberg, Laura A Huppert, Balazs Halmos, et al.
The Oncologist|July 27, 2025
Prevalence and impact of frailty on unplanned hospitalizations among adult patients with cancer in TaiwanChang-Hsien Lu, Kun-Yun Yeh, Yu-Shin Hung, et al.
The Oncologist|July 22, 2025
Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapySatı Coşkun Yazgan, Kamil Kayaş, Çağatay Arslan, et al.
Pageof 571